|
|
 Previous Article | Table of Contents | Next Article 
CD40 Ligand Induces an Antileukemia Immune Response In Vivo
Dagmar Dilloo,
Michael Brown,
Marie Roskrow,
Wanyung Zhong,
Martha Holladay,
William Holden, and
Malcolm Brenner
From the Division of Bone Marrow Transplantation and Cell and Gene Therapy Program, St Jude Children's Research Hospital, Memphis, TN.
Leukemia cells may express tumor specific antigens in association with Class I and II major histocompatability complex (MHC) molecules. However, lack of expression of conventional costimulator molecules means that these cells tend to induce specific T-cell anergy rather than activation. CD40 ligand (CD40L) is a costimulator molecule that directly activates T cells and may promote antigen presentation by CD40-expressing cells, which include professional antigen presenting cells and B-acute lymphoblastic leukemia (ALL) cells from many patients. We determined whether transgenic expression of CD40L could enhance an antileukemia immune response using a CD40+ murine lymphoblastic (A20) leukemia and a CD40- myeloblastic (WEHI-3) leukemia in a tumor treatment model. Injection of otherwise nonimmunogenic A20 cells in the presence of CD40L induced an immune response active against preexisting A20 tumor at a distant site. Moreover, concomitant local secretion of transgenic interleukin-2 (IL-2) further amplified the antileukemic response induced and increased protection against preexisting tumor. In ex vivo studies, CD40 activation of A20 cells enhances the antigen presenting potential of A20 cells by upregulating expression of B7.1 (CD80), Class I and II MHC molecules, and increases expression of fas antigens. The importance of CD40 activation to the resulting antitumor response is further emphasized by the failure of transgenic CD40L to protect against the CD40- WEHI myeloblastic leukemia. Depletion studies showed the protective effects against A20 cells to be mediated by a combination of CD4+ and CD8+ T lymphocytes and by natural killer (NK) cells. These results suggest a means by which CD40+ leukemia cells may be rendered immunogenic in vivo.
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 1927-1933
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Glouchkova, B. Ackermann, A. Zibert, R. Meisel, M. Siepermann, G. E. Janka-Schaub, U. Goebel, A. Troeger, and D. Dilloo
The CD70/CD27 Pathway Is Critical for Stimulation of an Effective Cytotoxic T Cell Response against B Cell Precursor Acute Lymphoblastic Leukemia
J. Immunol.,
January 1, 2009;
182(1):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Troeger, L. Glouchkova, B. Ackermann, G. Escherich, R. Meisel, H. Hanenberg, M. L. den Boer, R. Pieters, G. E. Janka-Schaub, U. Goebel, et al.
High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95
Blood,
August 15, 2008;
112(4):
1028 - 1034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Labbe, A. H. Tran, and C. J. Paige
Murine Model of Immune-Mediated Rejection of the Acute Lymphoblastic Leukemia 70Z/3
J. Immunol.,
May 1, 2006;
176(9):
5354 - 5361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Rousseau, E. Biagi, A. Dutour, E. S. Yvon, M. P. Brown, T. Lin, Z. Mei, B. Grilley, E. Popek, H. E. Heslop, et al.
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
Blood,
February 15, 2006;
107(4):
1332 - 1341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagi, R. Rousseau, E. Yvon, M. Schwartz, G. Dotti, A. Foster, D. Havlik-Cooper, B. Grilley, A. Gee, K. Baker, et al.
Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia
Clin. Cancer Res.,
October 1, 2005;
11(19):
6916 - 6923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Esplugues, J. Vega-Ramos, D. Cartoixa, B. N. Vazquez, I. Salaet, P. Engel, and P. Lauzurica
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy
Blood,
June 1, 2005;
105(11):
4399 - 4406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Biagi, G. Dotti, E. Yvon, E. Lee, M. Pule, S. Vigouroux, S. Gottschalk, U. Popat, R. Rousseau, and M. Brenner
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes
Blood,
March 15, 2005;
105(6):
2436 - 2442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Bergwelt-Baildon, B. Maecker, J. Schultze, and J. G. Gribben
CD40 activation: potential for specific immunotherapy in B-CLL
Ann. Onc.,
June 1, 2004;
15(6):
853 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol.,
September 15, 2003;
21(18):
3526 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rieger and T. J. Kipps
CpG Oligodeoxynucleotides Enhance the Capacity of Adenovirus-mediated CD154 Gene Transfer to Generate Effective B-Cell Lymphoma Vaccines
Cancer Res.,
July 15, 2003;
63(14):
4128 - 4135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Briones, J. M. Timmerman, D. L. Panicalli, and R. Levy
Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules
J Natl Cancer Inst,
April 2, 2003;
95(7):
548 - 555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
153 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells
Blood,
June 17, 2002;
100(1):
200 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Briones, J. Timmerman, and R. Levy
In Vivo Antitumor Effect of CD40L-transduced Tumor Cells as a Vaccine for B-Cell Lymphoma
Cancer Res.,
June 1, 2002;
62(11):
3195 - 3199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi
Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance
J. Exp. Med.,
February 11, 2002;
195(4):
423 - 435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Gruber, D. C. Skelton, and D. B. Kohn
Requirement for NK Cells in CD40 Ligand-Mediated Rejection of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cells
J. Immunol.,
January 1, 2002;
168(1):
73 - 80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda, M. J. Cantwell, S. J. Woods, L. Z. Rassenti, C. E. Prussak, and T. J. Kipps
CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
Blood,
November 1, 2000;
96(9):
2917 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kikuchi, M. A. S. Moore, and R. G. Crystal
Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
Blood,
July 1, 2000;
96(1):
91 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Francisco, K. L. Donaldson, D. Chace, C. B. Siegall, and A. F. Wahl
Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14
Cancer Res.,
June 1, 2000;
60(12):
3225 - 3231.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. A. Tripp, L. Jones, L. J. Anderson, and M. P. Brown
CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse
J. Immunol.,
June 1, 2000;
164(11):
5913 - 5921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, H. Suzuki, Y. Yuza, M. Akiyama, N. Ohno, and Y. Eto
An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium
Blood,
February 15, 2000;
95(4):
1258 - 1263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Cardoso, J. P. Veiga, P. Ghia, H. M. Afonso, W. N. Haining, S. E. Sallan, and L. M. Nadler
Adoptive T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Preclinical Studies
Blood,
November 15, 1999;
94(10):
3531 - 3540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hirano, D. L. Longo, D. D. Taub, D. K. Ferris, L. S. Young, A. G. Eliopoulos, A. Agathanggelou, N. Cullen, J. Macartney, W. C. Fanslow, et al.
Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand
Blood,
May 1, 1999;
93(9):
2999 - 3007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Ford, B. Barnhart, S. Shone, and L. R. Covey
Regulation of CD154 (CD40 Ligand) mRNA Stability During T Cell Activation
J. Immunol.,
April 1, 1999;
162(7):
4037 - 4044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kutubuddin, H. J. Federoff, P. M. Challita-Eid, M. Halterman, B. Day, M. Atkinson, V. Planelles, and J. D. Rosenblatt
Eradication of Pre-Established Lymphoma Using Herpes Simplex Virus Amplicon Vectors
Blood,
January 15, 1999;
93(2):
643 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Baker, A. G. Eliopoulos, L. S. Young, R. J. Armitage, C. D. Gregory, and J. Gordon
Prolonged Phenotypic, Functional, and Molecular Change in Group I Burkitt Lymphoma Cells on Short-Term Exposure to CD40 Ligand
Blood,
October 15, 1998;
92(8):
2830 - 2843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nakajima, T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S.-i. Yoshino, H. Yagita, and K. Okumura
Antitumor Effect of CD40 Ligand: Elicitation of Local and Systemic Antitumor Responses by IL-12 and B7
J. Immunol.,
August 15, 1998;
161(4):
1901 - 1907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
